17 research outputs found
A Study Of Internet Search Engines Usage By Undergraduate Students In Some Universities In The Niger Delta Region Of Nigeria
The purpose of this study is to investigate students’ ability to use different Internet search engines (ISEs) in Universities in the Niger Delta Region of Nigeria. To reveal the types of ISEs used, and identify the source through which students acquire the skills. The study adopted a descriptive survey method. Questionnaire and interview method was adopted to collect data. A total of 300 completed and returned copies were used for analyses using frequency counts and simple percentage to answer the research questions, and Z -test statistical tool to test formulated hypotheses. The study revealed that majority of the students occasionally use Internet search engines to retrieve information resources. The study also revealed tha t student use ISEs for the main purpose of retrieving information to meet their academic information needs. Problems such as lack of institutional computer laboratory with Internet connectivity for training on the use of Internet search engines, and inadequate knowledge of search skills/strategies of ISEs. It was found that there is significant difference between male and female students in the frequency of use of Internet search engines. The study will enable the students know the different Internet search engines to be utilized and different search strategies to use when searching for materials for their academic work
Obstacles Confronting Postgraduate and Undergraduate Students in Utilizing and Accessing Academic Library Resources: A Case Study
Frequencies of Some of the Problems Hampering Optimal Utilisation of e-Resources in Two Nigerian Federal Universities
Out-of-equilibrium CO2/HCO3− solutions and their use in characterizing a new K/HCO3 cotransporter
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.